Assenagon Asset Management S.A. Takes $264,000 Position in Theravance Biopharma, Inc. $TBPH

Assenagon Asset Management S.A. bought a new stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 23,980 shares of the biopharmaceutical company’s stock, valued at approximately $264,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Theravance Biopharma by 3.5% in the 1st quarter. Vanguard Group Inc. now owns 2,080,463 shares of the biopharmaceutical company’s stock valued at $18,579,000 after buying an additional 69,919 shares in the last quarter. Park West Asset Management LLC grew its holdings in shares of Theravance Biopharma by 0.6% during the 1st quarter. Park West Asset Management LLC now owns 1,804,244 shares of the biopharmaceutical company’s stock valued at $16,112,000 after purchasing an additional 11,256 shares during the last quarter. Nuveen Asset Management LLC grew its holdings in shares of Theravance Biopharma by 10.9% during the 4th quarter. Nuveen Asset Management LLC now owns 495,727 shares of the biopharmaceutical company’s stock valued at $4,665,000 after purchasing an additional 48,635 shares during the last quarter. Nuveen LLC bought a new stake in shares of Theravance Biopharma during the 1st quarter valued at approximately $3,348,000. Finally, Wellington Management Group LLP grew its holdings in shares of Theravance Biopharma by 3.7% during the 4th quarter. Wellington Management Group LLP now owns 198,491 shares of the biopharmaceutical company’s stock valued at $1,868,000 after purchasing an additional 7,162 shares during the last quarter. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Theravance Biopharma news, SVP Rhonda Farnum sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $11.39, for a total transaction of $113,900.00. Following the sale, the senior vice president directly owned 326,918 shares of the company’s stock, valued at $3,723,596.02. The trade was a 2.97% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 6.90% of the stock is owned by insiders.

Theravance Biopharma Price Performance

TBPH opened at $14.07 on Monday. Theravance Biopharma, Inc. has a fifty-two week low of $7.88 and a fifty-two week high of $14.55. The firm has a market capitalization of $708.57 million, a price-to-earnings ratio of 58.63 and a beta of 0.04. The company’s 50 day moving average price is $12.92 and its two-hundred day moving average price is $10.94.

Wall Street Analysts Forecast Growth

TBPH has been the topic of several research reports. Jones Trading raised shares of Theravance Biopharma to a “strong-buy” rating and set a $24.00 price target on the stock in a report on Tuesday, June 17th. Zacks Research lowered shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, September 15th. Wall Street Zen raised shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 16th. B. Riley initiated coverage on shares of Theravance Biopharma in a report on Friday, September 12th. They set a “buy” rating and a $28.00 price target on the stock. Finally, BTIG Research lifted their price target on shares of Theravance Biopharma from $24.00 to $25.00 and gave the company a “buy” rating in a report on Friday, June 27th. Two investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $23.00.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.